Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

Study Overview
=================
Brief Summary
-----------------
The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.

Detailed Description
-----------------
It has been hypothesized that intraocular (IOP) variability is an independent risk factor for the progression of glaucoma. IOP variability includes 24 hour IOP fluctuation during the waking period (diurnal fluctuation) and sleep period (nocturnal fluctuation) as well as longitudinal IOP variability measured in the diurnal period over the course of multiple office visits. Latanoprost has been clinically used to lower eye pressure in glaucoma and ocular hypertension for almost 10 years. Latanoprost 0.005% has been demonstrated to provide superior ocular hypotensive efficacy compared with timolol 0.5% in pivotal phase 3 clinical trials (Alm et al. 1995; Camras 1996). The Pattern Electroretinogram (PERG) is a non-invasive technology that objectively measures the retinal ganglion cell (RGC) function (Porciatti and Ventura 2004). A recent study has demonstrated that the RGC function can be improved following IOP reduction in glaucomatous eyes with early visual field defects (Ventura and Porciatti 2005). The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.

Official Title
-----------------
Relationship Between Intraocular Pressure Fluctuation and Retinal Ganglion Cell Function in Eyes Receiving Latanoprost 0.005% Versus Placebo

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Drug: latanoprost 0.005%
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion Criteria - OHT: Ocular hypertension defined as an IOP ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye Normal optic disc Normal visual field defined as follows: Mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5% Normal Glaucoma Hemifield Test (GHT) Reliable visual field exam (less than 33% false positives or false negatives, and less than 20% fixation losses) Inclusion Criteria - POAG: Glaucomatous visual field loss defined as a CPSD (p < 0.05), or GHT (p < 1%) outside normal limits with consistent with ONH or NFL defect Early visual field loss defined as MD ≤ -6.0 dB Untreated IOP ≤ 32 mmHg ONH or NFL defect defined as either inter-eye CDR asymmetry > 0.2, rim thinning or notching, or NFL bundle defect visible on slitlamp biomicroscopy and stereo color fundus photography Exclusion Criteria: Exclusion Criteria - OHT: Best-corrected visual acuity less than 20/40 either eye Abnormal or unreliable VF Untreated IOP > 32 mmHg Age < 18 or >85 years Refractive error of > +3.00 D or < -7.00 D Previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation Need for chronic ocular or systemic corticosteroid use Narrow/closed angle (gonioscopy must show 75% or more of the angle to be Grade 2 or more by Shaffer's grading system) Diabetic retinopathy Other diseases that may cause VF loss or optic disc abnormalities Life-threatening or debilitating illness making it unlikely patient could successfully complete the study Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil Refusal of informed consent or of commitment to the full length of the study Contraindication to latanoprost or placebo vehicle Exclusion criteria - POAG: Best-corrected visual acuity less than 20/40 Untreated IOP > 32 mmHg Age < 18 or >85 years Refractive error of > +3.00 D or < -7.00 D Previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation Diabetic retinopathy Other diseases that may cause VF loss or optic disc abnormalities Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil Inability to perform reliably on automated VF testing Life-threatening or debilitating illness making it unlikely patient could successfully complete the study. Refusal of informed consent or of commitment to the full length of the study Contraindication to latanoprost or placebo vehicle

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| primary open angle glaucoma<br>Patients with glaucomatous optic neuropathy defined as narrowing of the neuroretinal rim, notching, excavation, or RNFL defect; and repeatable standard automated perimetry abnormality defined as a glaucoma hemifield test (GHT) outside normal limits or pattern standard deviation (PSD) outside 95% normal limits were included. | Drug: latanoprost 0.005%<br>* Active comparator<br>* Other names: Xalatan;Drug: Placebo<br>* Placebo comparator<br>* Other names: Inactive tear drops;|
| Ocular Hypertensive group<br>Ocular hypertension defined as an intraocular pressure ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye, with normal optic disc, normal visual field defined as follows mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5%, normal Glaucoma Hemifield Test (GHT) and reliable visual field exam | Drug: latanoprost 0.005%<br>* Active comparator<br>* Other names: Xalatan;Drug: Placebo<br>* Placebo comparator<br>* Other names: Inactive tear drops;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function | RGC function is evaluated by pattern electroretinogram optimized for glaucoma (PERGLA) | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, intraocular pressure, latanoprost, retinal ganglion cell, pattern electroretinogram